A B S T R A C T A hereditary dysfibrinogenemia associated with defective aggregation of fibrin monomers was found in a 39-yr-old female and in the members of her immediate family, who had all been asymptomatic.
INTRODUCTION
Many of the dysfibrinogenemias reported thus far fall into a category with abnormal polymerization of fibrin monomer with or without altered releases of fibrinopeptides (1) (2) (3) . The functional abnormalities associated with abnormal polymerization have not been located on a molecular level, except in fibrinogen Detroit (4, 5) , to the replacements of amino acid residues or to the functional domains where the polymerization sites have been identified. In this paper, we report a congenital dysfibrinogenemia, designated as fibrinogen Tokyo II, with a substantially delayed polymerization of fibrin monomer that is probably due to an abnormality in the polymerization site on the DD domain of fibrin molecules, which are unfolded so that they can function when two fibrin molecules are linearly aligned.
METHODS
Blood collections. Venous blood was collected by the twosyringe method. A 2-ml portion was placed in a plain glass tube and allowed to clot at 37°C for 2 h to harvest serum. Another 2-ml portion was transferred to a glass tube containing EDTA and used for blood cell counting and preparation of EDTA plasma for assays of plasma proteins including fibrinogen. The other portion was anticoagulated with 1/9 vol of 3.8% trisodium citrate; platelet-rich and platelet-poor plasmas were prepared for the platelet aggregation and blood coagulation studies, respectively.
Hemostasis and coagulation tests. Hemostatic and coagulation studies were performed by standard procedures (6, 7) or as described elsewhere (8) , unless otherwise stated. Factor XIII (XIII)' was determined immunochemically by Laurell's method (9) using antisera purchased from BehringWerke AG, Marburg/Lahn, West Germany as well as by measuring the fluorescence of incorporated monodansyl cadaverine into casein, basically according to Lorand et al. (10) . Plasma fibrinogen was determined by four methods: (a) the thrombin time method essentially according to Clauss (11) using a fibrinogen determination kit (Dade, Miami, FL), (b) the method of Ratnoff and Menzie (12) , (c) the method of Laurell (9) , and (d) the turbidimetric method-0.1 ml of EDTA-plasma diluted with 3.0 ml of 0.5% EDTA-K2 in physiological saline was heated at 56°C for 10 min and the resulting turbidity was measured at 660 nm. Concentrations of fibrinogen in the sample were obtained on a calibration curve made with dilutions of a pooled plasma containing a known amount of fibrinogen. The thrombin time was performed as follows: 0.1 ml of either imidazole-buffered saline (IBS; one part of 0.257 M imidazole buffer, pH 7.4, and nine parts of physiological saline) or 0.025 M CaC12 was added to 0.1 ml of plasma, and the mixture was warmed at 37°C for 2 min. 0.1 ml of 10 NIH-U/ml thrombin ([Thrombin Topical from Parke, Davis & Co., Detroit, MI] was dissolved in 50% glycerol to give 1,000 NIH-U/ml, stored at -20°C and diluted as previously described with IBS just prior to use) was then added, and a clotting time was obtained in duplicate with a fibrometer (Becton, Dickinson & Co., Cockeysville, MD). The Reptilase time was performed by replacing thrombin with a 50 ug/ml solution of Reptilase, venom of Bothrops atrox (Reptilase-R, Pentapharm, Switzerland).
Purification of fibrinogen. About 130 ml of acid-citratedextrose-plasma derived from the propositus or healthy adults was passed through lysine-agarose (13) and gelatinagarose (14) columns connected in tandem at 22°C. The agarose was Sepharose 4B (Pharmacia Fine Chemicals, Uppsala, Sweden). Fibrinogen was precipitated from this plasma by either 25% ammonium sulfate saturation (repeated three times) or the method of Blomback and Blomback (15) . The fibrinogen fractions were dissolved in appropriate volumes of 0.3 M NaCl which was extensively dialyzed against the same solution and stored frozen in small aliquots at -80°C until used. In general, the purity of fibrinogen in various samples prepared by these two methods fell between 90 and 95% as estimated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (16) .
Studies on purified fibrinogen and its derivatives. The thrombin and Reptilase times were measured similarly as described above on plasma samples using 0.05 M Tris-HCl, pH 7.6, containing 0.1 M NaCl, instead of IBS. Thrombin clottability was estimated by the ratio of thrombin clottable protein to total protein, as determined by the method of Ratnoff and Menzie (12) . Immunoelectrophoresis was performed at a constant current of 3 mA/cm width for 90 min using 0.8% agarose (Nakarai Chemicals, Ltd., Kyoto, Japan) in barbital buffer, ionic strength 0.05, pH 8.6 . Gels were stained with Coomassie Brilliant Blue R-250 (Nakarai Chemicals). DEAE-cellulose chromatography was carried out as described by Finlayson and Mosesson (17) . Cross-linking of fibrin mediated by activated factor XIII (XIIIa) were examined by SDS-PAGE using 5.0 or 7.5% gels as well as by the clot solubility test in 1.0% monochloroacetic acid (18) . Total release of fibrino-peptides by either thrombin or Reptilase and aggregation of fibrin monomer were studied essentially according to Gralnick et al. (19) Binding study using Sepharose conjugated with fibrin monomer or with plasmic digests of cross-linked fibrin. Fibrinmonomer-Sepharose was prepared from normal fibrinogen essentially according to Heene and Matthias (25) , packed into a small column (gel vol = 4 ml), and equilibrated with 0.05 M Tris-H3PO4, pH 7.6, containing 0.1 M NaCI, 0.005 M EDTA, and 5 KIU/ml aprotinin (buffer A). A gradient employing pH (7.6 -4.1) and NaCl (0.1 a 2.0 M) was applied for elution using 0.05 M Tris-H3PO4, pH 4.1, containing 2.0 M NaCl, 0.005 M EDTA, and 5 KIU/ml aprotinin (buffer B1). 1-ml fractions were collected.
Sepharose conjugated with the plasmic digests of normal cross-linked fibrin was prepared as follows: 57.5 mg of fragment DD and 19.8 mg of fragments El + E2 (fragment E1+2), as estimated on the basis of an extinction coefficient of E2801% = 20.8 for fragment DD and 10.2 for fragment E (26), were mixed with 5 ml each of CNBr-Sepharose 4B gel (27) . Fragment DD was confirmed to be fairly homogeneous, but fragment E1+2 was an approximately 1:1 mixture of El and E2 which contained a trace amount of E3, if any, as depicted in Fig. 1 . Approximately 86.5% of fragment DD and 93.6% of fragment E1+2 were conjugated to the Sepharose gels. After treatment with 1 M monoethanolamine, pH 8.0, the gels were extensively washed with chilled 0.1 M NaHCO3, pH 8.9, containing 0.5 M NaCl and packed into small columns. The packed DD-and E1+2-conjugated Sepharose gels (3.5 (El + E2) (gel B) derived from normal cross-linked fibrin that was conjugated to the CNBr-activated Sepharose 4B. The three-subunit polypeptides of normal fibrinogen (mol wt: Aa = 65,000, B,B = 55,000, and 'y = 47,000) are shown as reference in gel C. A constant current of 7 mA/gel was applied to 7.5% gels. Gels were stained with Coomassie Brilliant Blue R-250.
(0.1 1.0 M), and urea (0 -6 M) gradients, using buffer B2. 1-ml fractions were collected.
The affinity chromatography was performed by using the same column for normal and abnormal samples in order to compare chromatograms as precisely as possible. For each run, these columns were regenerated by washing with sufficient amounts of buffer B, for fibrinmonomer-Sepharose and buffer B2 for DD-or Ei+2-Sepharose as well as with 0.1 M CH3COOH. The gels were then equilibrated with buffer A for repeated use. The binding capacity of the gels was confirmed to be unaltered since it was observed that the chromatograms were almost similar as long as identical samples were applied.
RESULTS
Case history and family study A 39-yr-old female inpatient at the gynecological ward had been examined for hemostasis and blood coagulation before she underwent hysterectomy for a uterine myoma. She had experienced neither excessive bleeding nor thrombotic tendency. Since the preoperative coagulation study revealed a markedly prolonged thrombin time and variable levels of plasma fibrinogen, we were prompted to further investigate her plasma. Some of her immediate family members investigated were also found to have a similar abnormality of fibrinogen, although they are all asymptomatic. Thus, the abnormality appears to be compatible with an autosomal dominant trait; no consanguinity was known to the family (Fig. 2) .
Hemostasis and coagulation studies
The bleeding time, whole blood clotting time, platelet counts, and platelet aggregation were normal but the one-stage prothrombin time, 15.8 s (control, 11.3 s), and activated partial thromboplastin time, 37.9 s (control, 21.3 s), were moderately prolonged. In thrombelastography, there was a moderately prolonged clot formation time, 13.0 min (normal, 5.4±1.0 min), and reduced maximum amplitude, 35 Table I . Studies on purified fibrinogen and its plasmic fragments Gross molecular structure. Molecular weights of fibrinogen Tokyo II and its three subunit polypeptides and the cross-linking pattern made by XIIIa were identical with those of normal fibrinogen when examined by SDS-PAGE (pattern not shown). Fibrinogen Tokyo II was also indistinguishable from normal fibrinogen by DEAE-cellulose chromatography (profile not shown) and immunoelectrophoresis (Fig. 7, wells 1 and 2) .
Thrombin and Reptilase times. As shown in Table  II , the thrombin and Reptilase times were markedly prolonged; virtually no solid fibrin clots were formed in more than 40 min. The addition of CaCl2 corrected the clotting times remarkably, but still only partially.
Release of total fibrinopeptides. When the release of total fibrinopeptides was studied at timed intervals after the addition of thrombin or Reptilase, no substantial differences were noted between the patient's and normal fibrinogens (pictures not shown).
Aggregation of fibrin monomer. Markedly altered aggregation was observed in the patient's fibrin monomer when compared with normal ones. The alteration depends on the ionic strength and thus virtually no aggregation was observed when the concentration of NaCl was increased to 0.05 M or more in 0.06 M potassium phosphate, pH 6.8. When normal fibrin monomer was mixed with 1/3 vol of either 0.02 M acetic acid or the patient's fibrin monomer, the aggregation profiles were almost similar; this shows that the patient's fibrin monomer per se would not inhibit the polymerization of normal fibrin monomer (pictures not shown).
Binding studies by means of affinity chromatography (Fig. 4) . The eluted fractions were combined as indicated, concentrated, and subjected to SDS-PAGE to confirm the molecular size and structure. As shown in Fig. 5 was eluted between fractions 23 and 32, which corresponded to much higher concentrations of 3.4-4.8 M urea. The eluted proteins of fragment DD derived from abnormal as well as normal fibrinogens both exhibited the DD-structure as shown by SDS-PAGE (Fig.  5, right panel) . The discrete elution profiles clearly show that fragment DD derived from fibrinogen Tokyo II has a significantly lower affinity than that from normal fibrinogen to fragment E1+2. Immunoelectrophoresis of fragment DD. When fragment DD derived from fibrinogen Tokyo II was compared with that from normal fibrinogen, more anodal migration was observed (Fig. 7, wells 3 and 4) . to 30 for both patient's (P) and normal (N) E1+2 fractions, and the combined peak fractions 8 and 9 for the patient's (P) and 26 and 27 for normal (N) fragment DD. 7.5% gels were stained with Coomassie Brilliant Blue R-250. Such an abnormal electrophoretic mobility was not as noticeable in fragment E1+2 (picture not shown) and fibrinogen (Fig. 7, wells 1 and 2 ).
DISCUSSION
Although impaired polymerization of fibrin monomer is the most common among the dysfibrinogenemias reported thus far (1-3) , the affected polymerization sites are not necessarily characterized in relation to the functional domains of fibrinogen molecules. Kudryk et al. demonstrated two functional sites of polymerization-one on the amino-terminal disulfide knot domain that is unfolded by thrombin and the other on the D domain which is already available in the molecule of fibrinogen-by using functional domains of the well-characterized abnormal fibrinogen, fibrinogen Detroit (5, 30) . Recently, however, Olexa and Budzynski postulated that four functional sites are involved in the polymerization step and depicted them by their flexible banana model of a bivalent fibrinogen molecule (31) . According to their model, there are two sets of binding sites on the NH2-terminal domain of the fibrinogen molecule that are designated as "A" and "B", their respective complementary sites are designated as "a" and "b" on the D domain. The "A" and "B" sites become available upon cleavage of fibrinopeptides A and B, respectively. While the "a" site does not need activation and is thus functional in the fibrinogen molecule, the "b" site becomes functional only when two D domains of different molecules have been linearly aligned to form a bivalent "bb." By using Sepharose conjugated with either normal noncrosslinked fibrin, plasmic fragment E1+2 (a mixture of fragments E1 and E2), or fragment DD, we showed that fragment DD derived from the patient's cross-linked fibrin was eluted at distinctly lower concentrations of urea (1.0-2.2 M) and around neutral pH (7.1-6.4) while that derived from cross-linked normal fibrin was recovered at much higher concentrations of 3.4-4.8 M urea and lower pH (5.5-4.8). In the reverse situation, i.e., the elution of the patient's and the normal fragments E1+2 from the DD-conjugated Sepharose, the elution profiles were nearly identical. Thus, the set "B"-"bb" would not function properly in fibrinogen Tokyo II owing to the impaired "bb" site on the aligned DD domain. It has been suggested that the set of polymerization sites "B"-"bb" induces side-to-side polymerization to form a fibrin sheet (31) . The defective binding between the E and DD domains found in fibrinogen Tokyo II could be also explained by the recently proposed model of Fowler et al. (32) . This model is based on an electron micrographic study in which they clearly showed the presence of trimer and pentamer complexes. In these complexes, the E domain of a fibrin monomer is attached to the linearly aligned DD domain of fibrinogen molecules, which is covalently cross-linked by XIIIa. In fibrinogen Tokyo II, the formation of a fibrin sheet by side-to-side aggregation or even protofibril formation by the "DEstag contact" designated by Fowler et al. (32) may thus be impaired. The polymerization site "b" on the D domain may be arranged at or near the XIIIa-mediated cross-link bonds, or these covalent bonds may align and stabilize the sites on the two fragment D moieties, as suggested by Olexa and Budzynski (31) . The XIIIa-mediated stabilization or facilitation of an aligned "bb" site may, at least in part, account for an accelerated polymerization and gelation of fibrin in the presence of Ca", which is observed in most abnormal fibrinogens (1-3) as well as the normal one (33, 34) . The XIIIa-mediated stabilization of the "bb" site may thus contribute to the formation of hemostatic thrombi in vivo where XIII and Ca++ are sufficiently available. This may also explain why little or no hemorrhagic tendency has been observed in many of the dysfibrinogemias in spite of a greatly prolonged thrombin clotting time in vitro. In our case, the propositus underwent surgery without any pathologic bleeding, though the "B"-"bb" set of Olexa and Budzynski (31) and the "DE-stag contact" of Fowler et al. (32) have been shown to function abnormally. The reason for this is not completely clear, but we presumed that the "bb" site without stabilization by cross-link bonds may not properly react with its complementary "B" site. However, the "bb" site when stabilized, may bind to the "B" site tightly enough to form the (DD)E moiety and promote polymerization of fibrin, although the binding capacity is significantly reduced compared with that of normal molecules. We did not conclusively study another set of polymerization sites, "A"-"a". However, we presumed that at least the "a" site on the D domain of fibrinogen Tokyo II functioned normally because the binding of the highly purified fibrinogen fraction to fibrinmonomer-Sepharose was virtually indistinguishable from that of the normal.
Based on these results and presumptions, we constructed a model which may illustrate the abnormal polymerization site on the DD domain in fibrinogen Tokyo II (Fig. 8 ).
There is a strong possibility that the abnormality resided in the DD domain of linearly aligned fibrin molecules; this was also supported by the abnormal electrophoretic mobility of fragment DD derived from the patient's fibrin. Since The other two functions ascribed to fibrinogen were apparently normal in fibrinogen Tokyo II, i.e., the release of total fibrinopeptides and the cross-linking by XIIIa to itself and other plasma proteins (28, 29, 35) .
Other features of fibrinogen molecules, including the gross molecular weight and subunit compositions as examined by SDS-PAGE, the chromatographic pattern on DEAE-cellulose, the circular dichroism spectra, and the immunologic reactivity, were all found to be normal.
We demonstrated that the impaired polymerization of fibrin monomer found in the dysfibrinogenemia, designated as fibrinogen Tokyo II, is partly, if not completely, attributable to a dysfunction of the polymerization site on the DD domain. Such an abnormality has not been observed in congenital dysfibrinogenemias reported thus far.
